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Abstract
Pemoline is a central ner vous system stimulant that has been used to treat attention-deficit hyperactivity disorder and narcolepsy
in humans; its identification in horses could be considered evidence of attempts to influence per formance. Two recent pemoline
‘positives’ in English racehorses led us to review the chemical relationships between tetramisole, levamisole, aminorex and pemoline.
Pemoline is a simple oxidation product of aminorex, which has been shown in the United States and elsewhere to be an equine
metabolite of levamisole. Based on the clear structural relationships between aminorex and pemoline, we conclude that levamisole
can metabolise to pemoline in horses and that pemoline identifications in horses post levamisole administration are likely to be
associated with levamisole administration. Levamisole should not be administered to horses about to compete because of its ability to
metabolise to two central ner vous system stimulants, aminorex and pemoline.

KEY WORDS: Horses, tetramisole, levamisole, aminorex, pemoline, metabolism, drug ‘positives’.

Pemoline, [(RS)-2-amino-5-phenyl-1,3-oxazol-4(5H)-one]
is a central ner vous system stimulant used to treat
attention-deficit hyperactivity disorder (ADHD) and
narcolepsy in humans (Molina and others 1981). In horse
racing, pemoline is classified as an Association of Racing
Commissioners International (ARCI) ‘Class 1’ foreign
substance, i.e., an agent with high potential to influence
per formance (Tobin 1981 and ARCI website). Pemoline
is unusually identified in a post-race sample, and its
identification would usually be interpreted as an attempt
to improperly influence per formance. However, an entirely
innocent explanation is possible for such pemoline
identifications, as we will now set forth.
The explanation is based on the fact that in the horse,
and possibly other species, pemoline is a metabolite of
levamisole, an anthelmintic and immune stimulant not
uncommonly administered to horses (Mohri and others
2005). The recommended dose in the horse is 2/mg/
kg orally, once a day for three-to-five days, as an immune
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modulator (Britt and Byars, 1997). Furthermore, in the
horse levamisole, metabolism has recently been shown
to produce a closely related substance, aminorex (Barker
2008, Ho and others 2009, Pellegrini, 2010). Aminorex,
which is structurally related to levamisole and pemoline
(Figure 1), is a central ner vous system stimulant which
was marketed as a prescription anorectic in Europe, but
withdrawn when it became associated with pulmonar y
hypertension (Gurtner 1985). In the United States,
Aminorex is a DEA Schedule 1 substance and an ARCI
‘Class 1’ substance, like pemoline.
In the United States, the link between levamisole
administration and aminorex identifications has been
associated with a series of no fewer than 82 aminorex
‘positives’ in post-race urines. These aminorex
‘positives’ star ted with a single identification in Belgium,
then, in the United States, first in October 2004 in
Ohio, and later in both Pennsylvania and Ontario (Weber
2010) as set for th in Table 1. In Pennsylvania, beginning

Table 1: Time Sequence of Aminorex “positives” in North America, 2004-2009
State/Province

2004

2005

2006

2007

2008

2009

Total

Ohio

8

2

9

4

1

4

28

4

32

Pennsylvania
Ontario
Totals

36
18

8

6

41

22

18
1

4

82

As shown in Table 1, ‘positive’ reports for aminorex in the
US and Canada peaked in 2006 with 41 total, followed by
18 in 2007, principally in Ontario. It seemed unusual that
these aminorex ‘positives’ continued to occur in the face
of significant penalties against the horsemen involved: the
penalty in Ohio usually being a fine of about $500, loss of
purse and a six-month suspension.
The first direct association between these aminorex
‘positives’ and levamisole administration was made by Dr
Frank Pellegrini of Freedom Health, LLC, whose companies’
products had been linked to the aminorex identifications.
Dr Pellegrini made the aminorex/levamisole association
in about September 2006 when at least one of a group of
horses that he had treated therapeutically with levamisole
gave rise to an Ohio aminorex ‘positive’ (Tobin 2010).
This finding led Dr Pellegrini and Freedom Health LLC
to perform a carefully designed series of experimental
administrations, using a number of different commercial
levamisole sources, a number of selected Freedom
Health products and two other non-levamisole wormers,
Panacur and Safe-Guard. The post administration urine
samples were then analyzed under contract by Industrial
Laboratories in Denver, CO, and this work confirmed Dr
Pellegrini’s proposed levamisole/aminorex relationship
(Pellegrini 2010). The formal reporting of these findings
on or about March 17th 2008 by Freedom Health, LLC, led
to an abrupt decline in the number of aminorex ‘positive’
calls (Table 1). This levamisole to aminorex transformation
was soon confirmed by the work of Dr Steve Barker of
Louisiana State University (Barker 2008) and later by Ho
and others (2009).
About this time our group in Kentucky was researching
the aminorex situation on behalf of Pennsylvania
horsemen, and a proposed chemical levamisole/aminorex
transformation mechanism was communicated by Dr
Rodney Eisenberg of Frontier Biopharm to Dr Mike Weber
in Ontario (Figure 1). In summary, work in 2006-2007 clearly
established that aminorex is found in equine urine post
levamisole administration and established a proposed
chemical mechanism for these transformations. These

findings led to forensic and regulatory re-evaluation of
the significance of the aminorex ‘positives’ reported in a
number of jurisdictions.
Review of the data presented in Table 1 shows differing
time courses of aminorex “positives” in each jurisdiction.
Pennsylvania reported no aminorex “positives” after 2006,
and eventually negotiated settlements with their horsemen.
In Canada, there were no aminorex “positives” tested
after 2007. On the other hand, Ohio continued testing
aminorex ‘positives’ until at least 2009, apparently largely
in Standardbred racing. Since drug testing continues at
about the same rate in each of these North American
racing jurisdictions, these changed positive call rates are
presumably due to horsemen recognising levamisole as
the source of many or most of these aminorex positives,
and possibly also to regulatory re-evaluation of the
forensic significance of very low concentration aminorex
identifications.
More recently, in October of 2009, we received a
communication from a colleague of an English horse
trainer who recently had two pemoline ‘positives’ and
one apparently related tetramisole ‘positive’ called (Tobin
2009). Responding to this request, we revisited the then
well-established link between levamisole and aminorex,
and reviewed the chemistry of levamisole, aminorex and
pemoline. The structure of pemoline is closely related
to that of aminorex, being a simple oxidation product of
aminorex. It is therefore easy to extend the levamisole/
aminorex connection from levamisole, (the levo isomer
of tetramisole, ergo the name levamisole) to aminorex
and then, by simple oxidation, to pemoline. Im summary,
any horse administered either levamisole or possibly
tetramisole is at risk of producing either aminorex or
pemoline positives, or, conceivably both, as set forth in
this abbreviated chemical reaction scheme in Figure 1.
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in October of 2005, testing indicated detections of
aminorex in both blood and urine samples and by
November 2006 aminorex ‘positives’ had been repor ted
in all four Pennsylvania racetracks (Mushalko, 2010,
Uboh, 2010). Each of these jurisdictions is a major
Nor th American racing jurisdiction, testing in the order
of 15,000 samples per year or more at multiple racing
venues, both Thoroughbred and Harness, in each
jurisdiction.

Figure 1: Proposed conversion of Levamisole to Aminorex to Pemoline.
Levamisole (1) can protonate to form intermediate 2, which can undergo
alkylation of the double bond to form 3, with loss of thiirane, 3.1, to yield
Aminorex 4. Aminorex can then undergo biological oxidation [O] to form
Pemoline 5 (Eisenberg 2008; Ho, 2009).
Furthermore, pemoline has an unusually long (150 hour)
apparent terminal half-life in horse urine and is thus likely
to yield prolonged ‘detection times’ in post-race urine
testing in horses, as shown by members of our research
group 30 years ago (Tobin 1981). As such, it seems
probable that one of the last metabolites to be detected
after levamisole administration would be pemoline, as has
apparently happened in the case of our English colleague,
Irish Veterinary Journal Volume 63 Number 8
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and as has also apparently occurred previously in English
racing (Tobin 2009).
Consistent with this proposed mechanism, the horses
involved in the recent English pemoline ‘positive’ had
been administered levamisole on the recommendation of
the trainer’s veterinarian. Levamisole was administered
as a clear yellow solution containing 3% w/v Levamisole
Hydrochloride Ph.Eur. Levacide 3% Drench, which is
described as a broad spectrum anthelmintic for use in
the treatment and control of nematode infections in cattle
and sheep. at 2.5ml per 10kg of bodyweight (.http://www.
norbrook.co.uk/products/ProductPrintable.cfm/product_
Key/425/CatKey/1/Section/Veterinary_Products/).
Consistent with the above chemistry, two of these horses
yielded positives for pemoline and a third horse was
reported positive for Tetramisole, entirely consistent with
the close structural relationship between levamisole and
tetramisole. (Tobin 2009).
With respect to the matter of the regulatory outcome of this
very unusual circumstance, we immediately communicated
the results of our researches as outlined in this report to
the trainer and veterinary surgeon involved. Additionally,
we can report that these findings were of relevance
to an enquiry held by the British Horseracing Authority
Disciplinary Department, in that “the Panel was satisfied
that the source of both pemoline and tetramisole was a
five-day course of 120ml of Levacide for [horse #1] and
[horse #2] and [horse #3] and a four-day course for [horse
#4], which commenced on August 18, 2009 and was given
under veterinary advice.” (http://www.britishhorseracing.
com/resources/about/whatwedo/disciplinary/
disciplinaryDetail.asp?item=091148)
In conclusion, administration of levamisole and presumably
also tetramisole to horses which are likely to be medication
tested should be avoided. This is because in the horse
levamisole, and possibly also tetramisole can metabolise
to two central nervous system stimulants, aminorex and
pemoline, and as such have been associated with ‘positive’
calls for each of these substances in post-race urines.
In point of fact, in the US, the link between levamisole
administrations and aminorex identifications has led to
the reclassification of levamisole, previously a substance
of essentially no regulatory interest, as an ARCI class
two agent (ARCI website). This is an explicit regulatory
recognition of the ability of levamisole administration to
produce aminorex ‘positives’ and now, based on these
English reports, pemoline ‘positives’ in post-race urines.
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